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Abstract
Background: Interaction with integrin and focal adhesion kinase (FAK) regulates the cancer cell adhesion
and invasion into extracellular matrix (ECM). In addition, phosphorylation of FAK correlates with the
increase of cell motility and invasion. Adhesion and spreading of cancer cells on a variety of ECM proteins,
including collagen type IV (Coll IV), leads to an increase in tyrosine phosphorylation and activation of FAK.
In this study, we investigated the mechanism of activation of FAK and its downstream extracellular signal-
regulated kinase (ERK)-1/2 signaling following stimulation by interleukin (IL)-1α and adhesion to ECM with
subsequent enhancement of pancreatic cancer cell adhesion and invasion.
Results: In immunoblotting analysis, all three pancreatic cancer cell lines (AsPC-1, BxPC-3, and Capan-2)
expressed the protein of FAK and β1 integrin. Enhancement of FAK protein association with β1 integrin
when cells were plated on Coll IV was more increased by stimulation with IL-1α. Preincubation with anti-
β1 integrin antibody and FAK siRNA transfection inhibited the association of FAK with β1 integrin of
pancreatic cancer cells. FAK phosphorylation was observed by adhesion to Coll IV, furthermore, stronger
FAK phosphorylation was observed by stimulation with IL-1α of pancreatic cancer cells adhered to Coll
IV in time-dependent manner. Genistein, a tyrosine kinase inhibitor, markedly inhibited the FAK
phosphorylation. IL-1α stimulation and Coll IV adhesion enhanced the activation of Ras, as evidenced by
the increased Ras-GTP levels in pancreatic cancer cells. Activation of Ras correlated with the
phosphorylation of ERK. While not statistical affecting the apoptosis of pancreatic cancer cells, IL-1α-
induced adhesion and invasion on Coll IV were inhibited with FAK gene silencing by siRNA, β1 integrin
blocking, and inhibition of FAK phosphorylation. PD98059, a MEK inhibitor, also inhibited IL-1α-induced
enhancement of adhesion and invasion in pancreatic cancer cells.
Conclusion:                   Our results demonstrated that activation of FAK is involved with the aggressive
capability in pancreatic cancer through Ras/ERK signaling pathway. Based on our results, we suggest that
the modification of IL-1, FAK, and integrins functions might be a novel therapeutic approach to aggressive
spread of pancreatic cancer.                
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Integrin binding to extracellular matrix (ECM) protein or
integrin crosslinking increases tyrosine phosphorylation
of focal adhesion kinase (FAK) [1,2]. FAK is a tyrosine
kinase considered a central molecule in integrin-mediated
signaling, and it is involved in cellular motility and pro-
tection against apoptosis [3-7]. The carboxyl-terminal
tyrosine residue (tyr397) of FAK, constitutes a major site of
phosphorylation, appears important for the tyrosine
phosphorylation of focal complex associated proteins,
and creates a high-affinity binding site recognized by the
SH-2 domain of the Src family [8,9]. In vitro, the N-termi-
nal domain of FAK binds directly to peptides correspond-
ing to the cytoplasmic domain of integrin β subunits
[2,10]. In addition, overexpression and phosphorylation
of FAK correlates with the increase of cell motility and
invasion [4,5,11,12]. Adhesion and spreading of cells on
a variety of ECM proteins, including collagen type IV (Coll
IV), leads to an increase in tyrosine phosphorylation and
activation of FAK [3,4,7]. Furthermore, suppression of
adhesion induced tyrosine phosphorylation of FAK may
interrupt cancer cell-ECM interactions and affect the inva-
sive and metastatic potential of cancer cells. Based on
these results, considerable evidence points to a critical role
of FAK participating in cancer cell-ECM interactions.
The integrin family ECM receptors are key mediators of
cell proliferation and cell survival. Integrin-mediated cell
adhesion is required for cell motility and also affects cell
proliferation and invasion in many systems [13-15]. We
previously proved that enhancement of α6β1-integrin
expression by interleukin (IL)-1α acting through IL-1
receptor type I (IL-1RI) plays an important role in meta-
static and invasive behaviors of pancreatic cancer, and
that strong expression of α6 integrin in cancerous tissues
significantly correlated with poor prognosis of pancreatic
cancer patients [15,16]. β1 integrin is also reported to play
an important role in invasiveness and metastasis forma-
tion of cancer cells [17-19].
Integrin-ECM interactions also activate signaling cascades
such as extracellular signal-regulated kinase-1/2 (ERK1/
2), mitogen activated protein kinase (MAPK), phosphati-
dylinositol 3-kinase (PI3-K), and Akt [2-5,20-23]. Espe-
cially, the downstream targets of Ras signaling pathway
are ERK1/2, which have been found to be regulated by
activation of FAK with respect to different matrix compo-
nents [3,21,24]. Therefore, integrin binding to the ECM
creates and activates a bipartite kinase complex and trans-
duces external stimuli from the ECM to the nucleus.
In this study, we investigated the mechanism of activation
of FAK and its downstream ERK1/2 signaling following
adhesion to ECM. Our results suggest that activation of
FAK enhances the adhesive and invasive capabilities of
pancreatic cancer cells through Ras/ERK signaling
pathway.
Results
Expression of FAK and β1 integrin in pancreatic cancer cells
In immunoblotting analysis, all three pancreatic cancer
cell lines also expressed FAK and β1 integrin (Fig. 1A). In
this study, we transfected all three pancreatic cancer cells
with siRNA that specifically targets FAK. Downregulation
of FAK protein expression by siRNA was confirmed by
immunoblotting. Transfection of siRNA resulted in a near
total loss of FAK expression (Fig. 1B).
Interaction between FAK and β1 integrin
In order to determine if FAK interacts with β1 integrin sub-
unit, β1 integrin was immunoprecipitated from cell lysates
of AsPC-1, BxPC-3, and Capan-2 cells and Western blot-
ted using anti-FAK antibody. As shown Fig. 2, more FAK
protein associated with β1 integrin when cells were plated
on Coll IV. Stimulation with recombinant human IL-1α
(rIL-1α) of pancreatic cancer cells on Coll IV furthermore
enhanced the association of FAK with β1 integrin. Preincu-
bation with anti-β1 integrin antibody and FAK siRNA
inhibited the association of FAK with β1 integrin of pan-
creatic cancer cells (Fig. 2).
Phosphorylation of FAK was enhanced by Coll IV adhesion 
and IL-1α stimulation
FAK activity was examined by FAK phosphorylation and
total tyrosine phosphorylation in AsPC-1, BxPC-3, and
Capan-2 cells. The lysates of pancreatic cancer cells were
analyzed by immunoprecipitation with antibodies to FAK
followed by Western blotting with an antibody which is
specific for anti-phosphotyrosine (4G10). FAK activation
was observed within 15 min of adhesion to Coll IV and
remained high for 60 min. (Fig. 3). Stronger FAK phos-
phorylation was observed by stimulation with rIL-1α of
pancreatic cancer cells adhered to Coll IV in time-depend-
ent manner (Fig. 3). In contrast, incubation with Genis-
tein, a tyrosine kinase inhibitor, markedly inhibited the
FAK phosphorylation.
Effect of FAK gene silencing and β1 integrin blocking on apoptosis of 
pancreatic cancer cells
After treated/untreated with FAK siRNA or control siRNA,
pancreatic cancer cells were incubated with/without anti-
β1 integrin antibody for 24 h, and then terminal deoxynu-
cleotidyl transferase-mediated nick end labeling (TUNEL)
assay was performed to investigate whether knockdown of
FAK expression and β1 integrin blocking had any effects
on pancreatic cancer apoptosis. Both FAK siRNA transfec-
tion and incubation with β1 integrin antibody induced a
slight increase in the apoptotic fraction of calls in normal
culture conditions, however, there was no statistical dif-
ference among these treatments (Table 1).Page 2 of 12
(page number not for citation purposes)
Molecular Cancer 2005, 4:37 http://www.molecular-cancer.com/content/4/1/37Expression of FAK and β1 integrin in pancreatic cancer cellsFigure 1
Expression of FAK and β1 integrin in pancreatic cancer cells. (A) FAK and β1 integrin protein expression in pancreatic cancer 
cell lines was determined in whole cell lysates by Western blotting analysis. Fifty micrograms of total cell lysates was separated 
on 10 % SDS-PAGE and transferred to polyvinylidene difluoride membranes. Membranes were probed with antibodies against 
FAK and β1 integrin. The β-actin Western blot served as a loading control. (B) Knockdown of FAK expression by siRNA was 
confirmed by immunoblotting in all three pancreatic cancer cells. Re-probing with an anti-β-actin antibody served as a control.Page 3 of 12
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FAK and β1 integrin subunit interaction in AsPC-1, BxPC-3, and Capan-2 cells. After incubating on Coll IV with 10 ng/ml IL-1α 
or 0.5 µg/ml anti-β1 integrin antibodies for 24 h, cells were added (2 × 105cells/well) to each well and incubated at 37°C and 5% 
CO2 for 30 min. After removing unattached cells, total cell lysates were immunoprecipitated with antibodies against β1 integrin 
subunit. Samples were resolved in 10 % SDS-PAGE gel under nonreducing conditions and transferred to polyvinylidene difluo-
ride membranes. Membranes were then probed with anti-FAK or anti-β1 integrin antibodies. Samples from cells incubated on 3 
% BSA were served as control.Page 4 of 12
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Phosphorylation of FAK in AsPC-1, BxPC-3, and Capan-2 cells. After incubating on Coll IV with 10 ng/ml IL-1α and/or 60 µM 
Genistein for 24 h, cells were added (2 × 105 cells/well) to each well and incubated at 37°C and 5 % CO2 for 15, 30, or 60 min. 
After removing unattached cells, cells were collected from each time point and lysed by lysis buffer and immunoprecipated with 
FAK antibody as described in Methods and materials. Effect of IL-1α and Genistein on Coll IV mediated phosphorylation of 
FAK was demonstrated. IP, immunoprecipitation; WB, Western blot.Page 5 of 12
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We investigated whether the inhibition of FAK had any
effects on adhesive and invasive response in pancreatic
cancer cells. Knockdown of FAK expression with siRNA
inhibited IL-1α-induced adhesion and invasion (Fig. 4A,
4B). The inhibitory antibodies against β1 integrin subunit
treatment similarly inhibited the IL-1α-induced enhance-
ment of adhesion and invasion in all three pancreatic can-
cer cells. Genistein and PD98059 (a MEK inhibitor) also
inhibited these enhancements of adhesion and invasion
by IL-1α stimulation in pancreatic cancer cells. While not
statistical affecting cellular apoptosis, the basal adhesive
and invasive capabilities of these cells were also sup-
pressed by siRNA, anti-β1 integrin antibody, Genistein,
and PD98059 (Fig. 4A, 4B). DMSO vehicle had no effect
on adhesion and invasion assays. These data suggest that
FAK regulation and β1 integrin subunit may have critical
roles in adhesive and invasive capabilities of pancreatic
cancer cells.
Activation of Ras and ERK pathway after IL-1α stimulation 
and Coll IV adhesion
We examined the activation of Ras/ERK pathway, a down-
stream target of FAK in pancreatic cancer cells, following
adhesion of cells to Coll IV for 15, 30, or 60 min. IL-1α
stimulation and Coll IV adhesion enhanced the activation
of Ras, as evidenced by the increased Ras-GTP levels in
three pancreatic cancer cell lines. Activation of Ras corre-
lated with the phosphorylation of ERK. In contrast, IL-1α
stimulation and Coll IV adhesion did not induce the Akt
phosphorylation (data not shown). These results indicate
that IL-1α and Coll IV adhesion may induce activation of
ERK through a Ras-dependent pathway as a downstream
of FAK activation (Fig. 5A). To evaluate whether FAK and
β1 integrin affect IL-1α-induced activation of Ras and ERK,
pancreatic cancer cells were transfected with FAK siRNA or
treated with anti-β1 integrin antibody for 30 min before
being exposed to rIL-1α for 30 min on Coll IV. Inhibition
FAK expression and β1 integrin function inhibited the acti-
vation of Ras and phosphorylation of ERK in three pancre-
atic cancer cell lines (Fig. 5B). These results suggest that
expression of FAK and β1-integrin has an important role in
regulating IL-1α-induced activation of signaling path-
ways. Detection of total ERK 1/2 levels served as a loading
control.
Discussion
In this report, we demonstrate that FAK plays a critical role
in adhesive behavior of pancreatic cancer cells via activat-
ing the Ras/ERK signaling pathways. FAK protein associa-
tion with β1 integrin was increased when cells were
attached on Coll IV and further increase was observed by
stimulating with IL-1α. Knockdown of FAK expression
with siRNA inhibited IL-1α-induced Ras/ERK activation
with subsequent inhibition IL-1α-induced adhesion and
invasion of pancreatic cancer cells on Coll IV while not
statistical affecting cellular apoptosis.
The activation of FAK following cell adhesion to Coll IV
and integrins engagement has been reported for many dif-
ferent cell types [3,4,7,25-27]. Recent reports have
strongly implicated the FAK phosphorylation of lung can-
cer cells in adhesion to Coll IV [7]. In this study, the phos-
phorylation of FAK in pancreatic cancer cells was
detectable with Coll IV adhesion in time-dependent man-
ner. Furthermore, stronger FAK phosphorylation was
observed by stimulation with IL-1α of pancreatic cancer
cells adhered to Coll IV. The tyrosine phosphorylation of
FAK was suppressed by Genistein, which has been
reported as a potent inhibitor of several tyrosine kinases.
It can be suggested that Genistein inhibits the activities of
protein tyrosine kinases (PTKs), which are active in the
upstream of FAK signaling pathway. Considering the
effect of Genistein on FAK phosphorylation, it can be sug-
gested that the induction of FAK phosphorylation in pan-
creatic cancer cells may proceed primarily through the
inhibition of a specific protein tyrosine phosphatase. For
instance, a dual-specific phosphatase, PTEN, has been
shown to be associated with FAK and capable of FAK
Table 1: Effect of FAK siRNA and β1 integrin blocking on apoptosis of pancreatic cancer cells
Apoptotic fraction (%)
Cell line Untreated Anti-β1 integrin antibody FAK siRNA Control siRNA
AsPC-1 1.37 ± 0.33 1.89 ± 0.51 2.20 ± 0.66 1.44 ± 0.54
BxPC-3 1.99 ± 0.31 2.38 ± 0.51 2.56 ± 0.53 2.02 ± 0.4
Capan-2 2.44 ± 0.30 2.59 ± 0.37 3.01 ± 0.52 2.50 ± 0.43
AsPC-1, BxPC-3, and Capan-2 cells were treated with anti-β1 integrin antibody, FAK siRNA, or control siRNA and incubated for 24 h, and then 
detection of apoptosis was performed by TUNEL assay and flow cytometry. Statistical significance was tested by one-way analysis of variance and 
post hoc test (Turkey Kramer multiple comparisons). All data are expressed as mean ± s.d. There was no significant difference among these 
treatments.Page 6 of 12
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Involvement of FAK phosphorylation and integrin signaling with adhesion and invasion of pancreatic cancer cells. (A) AsPC-1, 
BxPC-3, and Capan-2 cells were incubated with 10 ng/ml IL-1α, with 10 ng/ml IL-1α and 60 µM Genistein, with 10 ng/ml rIL-1α 
and 25 µM PD98059, or with 10 ng/ml rIL-1α and equivalent amounts of DMSO vehicle for 24 h. FAK siRNA transfected cells 
were cultured with 10 ng/ml IL-1α for 24 h. After incubating for 30 min with/without anti-β1 antibody, cell adhesion assay was 
performed at 37°C for 30 min. Statistical significance was tested by one-way analysis of variance and post hoc test (Turkey 
Kramer multiple comparisons). The p-values indicate statistical significance between data in controls and each treatment. Bars 
indicate the s.d.*: p < 0.05. (B) After incubation for 30 min with/without antibody against β1 integrin, AsPC-1, BxPC-3, and 
Capan-2 cells were cultured with 10 ng/ml IL-1α, with 10 ng/ml IL-1α and 60 µM Genistein, with 10 ng/ml rIL-1α and 25 µM 
PD98059, or with 10 ng/ml rIL-1α and equivalent amounts of DMSO vehicle for 24 h in the inner chamber coated with Coll IV. 
FAK siRNA transfected cells were cultured with 10 ng/ml IL-1α for 24 h in the inner chamber. Statistical significance was tested 
by one-way analysis of variance and post hoc test (Turkey Kramer multiple comparisons). The p-values indicate statistical signif-
icance between data in controls and each treatment. Bars indicate the s.d. *: p < 0.05.Page 7 of 12
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Involvement of FAK and β1 integrin subunit with the activation of Ras and ERK pathway in pancreatic cancer cells. Examination 
of Ras and downstream ERK activation was performed as described in Materials and Methods. Cell lysates were prepared 
according to the instructions provided in the Ras Activation Assay Kit, and affinity precipitation of GTP-bound Ras was per-
formed using GST-tagged Raf-RBD. Levels of pull-downed Ras (Ras-GTP) were determined by anti-Ras immunoblotting.(A) 
AsPC-1, BxPC-3, and Capan-2 cells were serum starved for 24 h and then attached to Coll IV with 10 ng/ml IL-1α for 15, 30, 
or 60 min. The time-dependent Ras activation and ERK1/2 phosphorylation by adhesion to Coll IV was demonstrated. Detec-
tion of total ERK 1/2 levels served as a loading control.(B) AsPC-1, BxPC-3, and Capan-2 cells were serum starved for 24 h 
and then attached to Coll IV with 10 ng/ml IL-1α in the presence or absence of inhibitory antibodies against β1 integrin subunit 
for 30 min. FAK siRNA transfected pancreatic cancer cells were attached to Coll IV with 10 ng/ml IL-1α. Effects of IL-1α, FAK 
gene silencing, and β1 integrin blocking on the activation of Ras/ERK signaling pathway in pancreatic cancer cells were demon-
strated. Detection of total ERK 1/2 levels served as a loading control.Page 8 of 12
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determine whether PTEN is associated with FAK in cancer
cells after adhesion to Coll IV.
There is accumulating evidence that supports an impor-
tant role of ERK pathway in promoting cell proliferation
and invasion of cancer cell [4,31-35]. It has been reported
in many cell lines that integrin dependent activation of
MAPK requires FAK [24,36,37]. Coll IV-dependent activa-
tion of ERK1/2 in intestinal epithelial cells also requires
FAK [3]. MAPK has been reported to regulate cell migra-
tion through the enhancement of myosin light chain
phosphorylation [38]. Thus, the requirement for FAK
activity in the efficient activation of MAPK could also be
related to the effects of FAK on cell motility [39,40]. In
addition, previous studies have indicated that loss of
integrin signaling, such as FAK gene silencing and
blocking of integrin signaling, can induce cellular apopto-
sis[14,20,41-44]. In contrast, these suppress of integrin
signaling is reported to decrease the invasive behavior but
not cellular apoptosis and proliferation in some cancer
cells[2,45]. In this study, the similarity in the time course
over which FAK and ERK1/2 were activated in response to
IL-1α and adhesion to Coll IV of pancreatic cancer cells
were observed. Both of knockdown of FAK expression
with siRNA and blocking of β1 integrin inhibited IL-1α-
induced Ras/ERK activation with subsequent inhibition
IL-1α-induced adhesion and invasion of pancreatic cancer
cells on Coll IV while not statistical affecting cellular
apoptosis. Furthermore, we demonstrated that a MEK
inhibitor PD98059 inhibited IL-1α-induced enhance-
ment of adhesion and invasion in pancreatic cancer cells.
Our results reveal that the relationship between FAK phos-
phorylation and the activation of its downstream Ras/ERK
signaling pathway has an important role in the adhesive
and invasive capabilities of pancreatic cancer cells. It has
also been reported that IL-1 plays an important role in
tumor invasion and angiogenesis [46-48]. Furthermore,
recent reports demonstrated the involvement of IL-1 with
the ERK1/2 signaling pathway activation [49-51]. Our
results in this work are supported with these reports.
Integrin mediated signaling to ERK1/2 is dependent on
the integrity of the actin cytoskeleton [52,53]. The disrup-
tion of cytoskeleton integrity completely inhibited
fibronectin stimulated FAK tyrosine phosphorylation and
ERK1/2 signaling. Also, in some cancer cells, the integrity
of the cytoskeleton structure is required for ECM gener-
ated signals to ERK1/2. β1 integrin is reported to play an
important role in adhesion and invasion of cancer cells
[17-19]. And several intracellular signals have been sug-
gested to mediate effects of IL-1, including activation of
MAPK. Activation of MAPK by IL-1 subsequently induces
the activator protein-1 and nuclear factor-κB DNA-bind-
ing activity, which promotes expression of the genes
involved in cell survival, proliferation, and angiogenesis
[54,55]. We also previously reported that the enhance-
ment of α6β1-integrin expression by IL-1α acting through
IL-1RI plays a critical role in adhesive and invasive behav-
iors in pancreatic cancer, and proved that the strong
expression of the α6 integrin subunit in pancreatic cancer
tissue significantly correlated with the poor prognosis and
the presence of hepatic metastases in pancreatic cancer
patients [15,16]. In this study, we investigated whether β1
integrin is physically associated with FAK or the activation
of β1 integrin mediated signaling is sufficient to activate
FAK in pancreatic cancer cells. We demonstrated that the
enhancement of adhesion and invasion to Coll IV in pan-
creatic cancer cells is dependent on the presence of β1
integrin. Furthermore, we proved that FAK phosphoryla-
tion correlated with the activation of its downstream Ras/
ERK signaling pathway. Our data indicates that the Coll
IV-induced phosphorylation of FAK correlated with phys-
ical association of FAK with β1 integrin with subsequent
the activation of ERK1/2 signaling pathways in pancreatic
cancer cells.
Conclusion
We demonstrated that IL-1α stimulation and cell adhe-
sion to Coll IV enhanced the FAK protein association with
β1 integrin and FAK phosphorylation. And these enhance-
ments correlated with the activation of Ras/ERK signaling
pathways in pancreatic cancer cells. IL-1α-induced activa-
tion of these signaling pathways can be inhibited by
knockdown of FAK expression with siRNA, consistent
with the inhibition of adhesive and invasive capabilities
of pancreatic cancer cells. Based on these results, we sug-
gest that the modification of IL-1, FAK, and integrins func-
tions might be a novel therapeutic approach to aggressive
spread of pancreatic cancer.
Methods
Cell culture
The human pancreatic cancer cell lines, AsPC-1, BxPC-3
and Capan-2, were provided from the American Type Cul-
ture Collection (Rockville, MD, USA). The AsPC-1 and
BxPC-3 cells were maintained in RPMI 1640 (Gibco BRL,
Eggenstein, Germany) supplemented with 10 % fetal calf
serum (FCS). Capan-2 cells were maintained in Dulbecco
modified Eagle medium (Gibco BRL) with high glucose
and 10 % fetal calf serum. All cells were incubated at 37°C
in a humidified atmosphere of 5 % CO2 in air.
Reagents and Antibodies
rIL-1α was provided by Diaclone (Besançon, France). Coll
IV (human) and Genistein were purchased from SIGMA
(Saint Louis, MO, USA). PD98059 was purchased from
New England Biolabs Inc (Beverly, MA, USA). The
monoclonal antibodies used included anti-β1 (P5D2)
from Chemicon International Inc. (Temecula, CA, USA);Page 9 of 12
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Upstate Biotechnology Inc. (Lake Placid, NY, USA). The
polyclonal anti-phospho-Akt (587F11), anti-phospho-
ERK 1/2 and anti-ERK 1/2 antibodies were from Cell Sig-
naling Technology (Beverly, MA, USA).
Western blot analysis
Cells were lysed in lysis buffer (50 mM Tris-HCl, pH 7.5,
150 mM NaCl, 1 mM CaCl2, 1 % Triton X-100, 0.1 % SDS,
0.1 % Nonidet P-40, 2 mM PMSF, 1 mM vanadate, 5 µg/
ml Trasylol, 10 µM Pepstatin A and 10 µM leupeptin).
Protein concentrations were determined with a BCA pro-
tein assay kit (Pierce, Rockford, IL, USA). The amounts of
samples were 50 µg per each lane. Lysates were separated
by 10 % SDS-polyacrylamide gel electrophoresis (SDS-
PAGE), transferred to polyvinylidene difluoride mem-
branes (Immobilon PVDF; Nihon Millipore Ltd., Tokyo,
Japan) and immunoblotted with each antibody. β-actin
Western blots were served as controls.
Immunoprecipitation
Pancreatic cancer cells lysates were centrifuged at 14,000
rpm at 4°C for 15 min and the supernatants (750 µg of
protein) were used for immunoprecipitation with either
anti-β1 integrin (P5D2) or anti-FAK (4.47) antibody at
4°C overnight. After incubation for 1 h with antibody,
either protein A- or protein G-sepharose was added to the
lysates and incubated overnight at 4°C. The bead bound
complexes were pelleted, washed several times with lysis
buffer in PBS and boiled with SDS sample buffer for 5 min
before loading on 10 % SDS-PAGE. For Western blot anal-
ysis, the proteins were transferred to polyvinylidene diflu-
oride membranes after SDS-PAGE Specific binding was
detected with the enhanced chemiluminescence system
(ECL; Amersham Life Science Ltd., Buckinghamshire,
United Kingdom).
RNA interference (siRNA)
Pancreatic cancer cells were transfected with siRNA for
FAK and with control nonspecific siRNA using FAK
siRNA/siAb™ Assay Kits (Upstate Biotechnology Inc.)
according to the manufacture's instruction. Briefly, cells
were grown in 35 mm dishes and overlaid with the trans-
fection mixture containing siRNA at a concentration of
200 pmol/well. After 4 h incubation, complete medium
with 10 % FCS was added and cells were incubated for
another 48 h.
TUNEL assay
Detection of apoptosis was performed by TUNEL assay.
After incubating for 24 h with/without anti-β1 integrin
antibody, pancreatic cancer cells were collected by centrif-
ugation, fixed in 4 % paraformaldehyde (pH 7.4) and
then stained and analyzed for apoptosis using an In Situ
Cell Death Detection Kit, Fluorescein (Roche Diagnostics
GmbH, Penzburg, Germany). Fixed cells were permeabi-
lized using a mixture containing terminal deoxynucleoti-
dyltransferase and fluorescein-dUTP at 37°C for 60 min.
Flow cytometric analysis using a FACS scan (Becton Dick-
inson Immunocytometry Systems, Mountain View, CA,
USA) was done to quantitate apoptosis[56].
Cell adhesion assay
Adhesion assay was performed as described previously
with some modifications [15]. 24-well plates were coated
either with Coll IV (5.0 µg/cm2) or 3 % bovine serum
albumin (BSA) in phosphate-buffered saline (PBS).
Briefly, after incubating for 24 h with/without rIL-1α (10
ng/ml), Genistein (60 µM), PD98059 (25 µM), or equiv-
alent amounts of DMSO vehicle, cells were added (2 × 105
cells/well) to each well and incubated at 37°C and 5 %
CO2 for 15, 30, or 60 min. After removing unattached
cells, the number of adherent cells was counted directly by
light microscopy. Before the stimulating experiments with
IL-1α were attempted, a concentration of 10 ng/ml was
determined to be the lowest effective concentration for
stimulating experiments (data not shown). In some exper-
iments, 0.5 µg/ml anti-β1 integrin antibodies were added
to cells for 30 min prior to seed to the well. Before the
blocking experiments were attempted, a concentration of
0.5 µg/ml was determined to be the lowest effective con-
centration for blocking experiments (data not shown).
Experiments were performed in triplicate and repeated at
least three times.
Cell invasion Assay
In vitro invasion assays were performed as described pre-
viously with some modifications [15]. Polycarbonate fil-
ters (6.3-mm diameter, 8- µm pore size) of cell culture
inserts (BD Biosciences Discovery Labware, Franklin
Lakes, NJ, USA) were coated with 5.0 µg/cm2 Coll IV. Can-
cer cells were added (1 × 105 cells/well) to the inner cham-
ber of a cell culture insert and incubated at 37°C for 24 h,
either with 10 ng/ml rIL-1α, with 10 ng/ml rIL-1α and 60
µM Genistein, with 10 ng/ml rIL-1α and 0.5 µg/ml of anti-
β1 integrin antibody, with 10 ng/ml rIL-1α and 25 µM
PD98059, or with 10 ng/ml rIL-1α and equivalent
amounts of DMSO vehicle. To quantitate invasion, the fil-
ters were fixed in 70 % ethanol for 30 min and stained
with Giemsa. Cells were removed from the upper surface
of the filters by rubbing gently with a cotton-tipped appli-
cator. Cells that had invaded through the membrane were
counted in five random microscope fields of the lower fil-
ter surface.
Ras activation assay
Ras activation state was determined using the Ras Activa-
tion Assay Kit provided from Upstate. Briefly, after serum
starved for 24 h, pancreatic cancer cells were incubated on
the 35-mm well coated with Coll IV (5.0 µg/cm2) inPage 10 of 12
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15, 30, or 60 min. Then, cells were harvested and lysed in
lysis buffer (100 mM HEPES, pH 7.5, 200 mM NaCl, 1 %
Nonidet P-40, 10 mM MgCl2, 5 mM EDTA and 10 % glyc-
erol), and supernatant prepared by centrifugation for 5
min at 4°C at 14,000 g. Ras-GTP from various treated
lysates was "pulled down" using the GST fusion protein
corresponding to human Ras binding domain of Raf-1
bound to agarose. The presence of Ras-GTP was detected
by Western blotting using anti-Ras antibody (Upstate). In
some experiments, 0.5 µg/ml anti-β1 integrin antibodies
were added to cells for 30 min prior to seed to the well.
Statistical analysis
Statistical comparisons were made using the Student's t
test for paired observations or by one-way ANOVA with a
post hoc test for multiple comparisons. Statistical
significance was indicated by p < 0.05. Data are presented
as mean ± standard deviation (s.d.). Each experiment was
repeated 3 times and was carried out in triplicate.
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